Relevant bibliographies by topics / Cancer Research Committee

Academic literature on the topic 'Cancer Research Committee'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer Research Committee.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer Research Committee"

1

Odei, Bismarck, Temitope Agabalogun, Erika Bello-Pardo, Christina C. Huang, Daniel Vanderbilt, Seyi Omeh, and Fumiko Chino. "Specialty representation on national comprehensive cancer network guideline committees." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 11041. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.11041.

Full text
Abstract:
11041 Background: Among the National Comprehensive Cancer Network (NCCN) guidelines, the existence of Category 1 evidence for cancer management decisions remains low, resulting in the reliance on multispecialty perspective to determine optimal treatment approach. Multiple studies suggest that the specialty composition of oncological teams is important in the trajectory of decision-making. Consequently, we sought to determine if there was adequate representation of radiation oncologists (ROs) on NCCN committees (NCMs). Methods: NCMs with Category 1 or 2A recommendations for radiotherapy use were identified. Committee members were documented including specialty, academic rank, and committee role. H-index and gender was assessed for each member. A minimum arbitrary threshold of < 10% was used to define underrepresentation of ROs. Univariate and multivariate (MVA) logistic regression identified factors predictive of underrepresentation. Results: Of 57 assessed guidelines, 38 (66.7%) NCMs recommended radiation as Category 1 or 2A from which a total of 1284 committee members were identified. Median committee size was 33 (range 29-38). Overall, 42.2% were Medical Oncologists (MOs), 23.9% were Surgical Oncologists (SOs), and 11.5% were ROs [22.4% were a mix of Radiologists, Pathologists, other specialty physicians, and non-physician members like Patient Advocates]. ROs constituted 4.4% of NCM Chairs (MOs: 68.9%, SOs: 13.3%, Other: 13.3%); 29% of Vice Chairs (MOs: 35.5%, SOs: 35.5%); and 5.9% of the discussion writing committee (MOs: 70.6%, SOs: 23.5%). The representation of ROs was highest for Head/ Neck Cancer NCM (38.8%) and Prostate Cancer NCM (25.8%). 42% of the NCMs recommending radiation had < 10% representation of ROs; 17% of guidelines recommending radiation had 1 or less RO including 4 NCMs which did not have a single RO committee member. On univariate analysis, factors predictive of RO underrepresentation were low SO representation (p = 0.038) and low median H-index of the NCM (p = 0.013); low proportion of full professors trended towards significance (p = 0.060). On MVA, median H-index had a negative association with RO underrepresentation (p = 0.038) —no association was found to rank, gender or specialty. Conclusions: Our study shows alarmingly low representation of ROs among NCCN committees which include radiation as a Category 1 or 2A recommendation. This can both limit the discussion during guideline development and negatively impact the diversity of perspectives in management recommendations. Efforts to ensure more proportional representation of ROs on NCCN guideline committees are warranted including exploring potential barriers to committee leadership.
APA, Harvard, Vancouver, ISO, and other styles
2

Birmingham, Karen. "Parliamentary committee examines UK cancer research efforts." Nature Medicine 6, no. 4 (April 2000): 360–61. http://dx.doi.org/10.1038/74583.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lyman, Gary H., and Harold L. Moses. "Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream." Journal of Clinical Oncology 34, no. 17 (June 10, 2016): 2061–66. http://dx.doi.org/10.1200/jco.2016.67.3160.

Full text
Abstract:
Precision medicine focuses on the management of individual patients on the basis of biomarkers and other distinguishing characteristics, with the overarching objective of improving clinical outcomes. The rapid proliferation of biomarker tests and targeted therapies has revolutionized patient care in a variety of serious disorders. Targeted cancer therapies interrupt oncogenic molecular pathways driven by mutations, overexpression, or translocation of specific genes. However, there is concern that the emergence of large-scale genomic data is exceeding our capacity to appropriately analyze and interpret the results. In 2014, the Institute of Medicine convened the Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies. This committee conducted a study to develop recommendations to address diverse and interconnected development, regulatory, clinical practice, and reimbursement issues. The committee conducted an extensive search of the relevant literature and invited testimony from a wide range of experts in the field. The final report of the committee’s study and deliberations was released on March 4, 2016, focusing on ways to achieve 10 goals to further advance the development and appropriate clinical use of biomarker tests for molecularly targeted therapies. This article presents an overview of the committee’s study and resulting recommendations, which cover establishment of clinical utility, regulatory oversight, coverage and reimbursement, health system data integration, as well as education and access. The committee’s recommendations presented and discussed here are fundamentally grounded in the understanding that, when properly validated and appropriately implemented, these assays and corresponding therapies hold considerable promise to enhance the quality of patient care and improve meaningful clinical outcomes.
APA, Harvard, Vancouver, ISO, and other styles
4

McGinnis, Lamar S. "Program planning committee chairman." Cancer 75, S7 (April 1, 1995): 1761–64. http://dx.doi.org/10.1002/1097-0142(19950401)75:7+<1761::aid-cncr2820751602>3.0.co;2-d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Price, Kandie C., Barbara K. Barrett, and Jean M. Roark. "Cancer and Leukemia Group B Clinical Research Associates Committee." Clinical Cancer Research 12, no. 11 (June 1, 2006): 3642s—3644s. http://dx.doi.org/10.1158/1078-0432.ccr-06-9014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goldberg, Richard M., Donna Niedzwiecki, Monica Bertagnolli, A. William Blackstock, Joel E. Tepper, and Robert J. Mayer. "Cancer and Leukemia Group B Gastrointestinal Cancer Committee: Table 1." Clinical Cancer Research 12, no. 11 (June 1, 2006): 3589s—3595s. http://dx.doi.org/10.1158/1078-0432.ccr-06-9004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Larsen, N. S. "Committee Recommends Triple Attack on Breast Cancer." JNCI Journal of the National Cancer Institute 85, no. 12 (June 16, 1993): 946–47. http://dx.doi.org/10.1093/jnci/85.12.946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kohman, Leslie J. "Cancer and Leukemia Group B Surgery Committee." Clinical Cancer Research 12, no. 11 (June 1, 2006): 3622s—3627s. http://dx.doi.org/10.1158/1078-0432.ccr-06-9010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Heron, Dwight Earl, Amanda Barry, Hans Benson, Zach Lorinc, and Kathleen Lokay. "The standardization of skin cancer treatment recommendations through the analysis of clinical pathways data and an evidence-based, physician-driven committee process." Journal of Clinical Oncology 34, no. 7_suppl (March 1, 2016): 147. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.147.

Full text
Abstract:
147 Background: Clinical pathways (CP) have the potential to improve the quality and safety of care and lead to more predictable outcomes and costs through standardization. Via Oncology’s CP program aims to standardize care at radiation centers across its nationwide network. Created through an evidence-based, physician-driven committee process, CP recommend the best treatment plan for specific patient populations based on a hierarchy of efficacy, toxicity, and cost. In the absence of definitive data, reaching a consensus on the best treatment recommendation is difficult, particularly for disease states such as melanoma, squamous cell carcinoma, and basal cell carcinoma for which a wide range of radiation doses and schedules are considered effective and regional and institutional preferences may vary. Methods: After initial implementation of CP, radiation disease committees meet semiannually to review treatment recommendations and utilization data collected for the prior six months. Data reflect treatment plans selected by physicians for individual patients. At the January 2015 skin pathway committee meeting, committee members reviewed data for each patient presentation to determine which doses and schedules were used most frequently. Results: After reviewing the utilization data, the committee narrowed the recommendations to one or two treatment plans per presentation, typically including standard and hypofractionated schedules. In scenarios where multiple treatment plans were selected at a similar frequency, the committee standardized to the lower dose and fewer fractionation plan. This reduced the number of treatment plans on the pathway from 34 to 15. A decrease in pathway adherence rates was not observed following this change. Conclusions: Data gathered from CP can be used to further standardize clinical care when there are several effective and accepted treatment regimens but a lack of published data. Through a dynamic process of assessing and modifying physician practice and patterns of care, CP provide cancer centers with a platform to ensure delivery of consistent, high-quality care to patients throughout their network.
APA, Harvard, Vancouver, ISO, and other styles
10

Mittman, Brian S., James W. Dearing, Kathleen Mazor, and James Nutter. "Dissemination, implementation, and quality improvement research within the HMO Cancer Research Network." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 215. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.215.

Full text
Abstract:
215 Background: The HMO Cancer Research Network, funded by the National Cancer Institute, provides infrastructure support to facilitate cancer research in non-profit integrated healthcare delivery systems. A key CRN goal to improve quality and outcomes through research and research-based methods for accelerating implementation of innovations in cancer care. Methods: The CRN is led by a Steering Committee and an Executive Committee. CRN Scientific Working Groups support activity within distinct areas; the CRN Communication and Dissemination Scientific Working Group (C&D SWG) supports the design, conduct and reporting of research on (1) communication and decision makin in cancer care and (2) dissemination and implementation of cancer research findings and best practices. C&D SWG activities include monthly calls presenting C&D research resources, project ideas and funding opportunities; individual consultation and technical assistance to support CRN researchers developing funding applications and conducting research in relevant areas; and mentorship for CRN Scholars. General CRN resources to facilitate research to improve cancer care quality include a multi-institution Virtual Data Warehouse with accompanying query tools to facilitate preparatory-to-research and collaborative research studies and specific cancer-related data items; funding for Developmental and Pilot Studies; and an Outreach and External Collaborations Core to facilitate research collaborations among (a) CRN institution-based scientists, (b) scientists at other institutions, and (c) clinical and operations partners. Results: The CRN C&D SWG continues to stimulate increased awareness and interest in conducting dissemination and implementation studies and quality improvement research in cancer care, and to support the development of new project ideas and funding applications and the successful completion and publication of such studies. Conclusions: CRN activities facilitate innovative multi-site, multi-disciplinary cancer studies in the integrated delivery system setting, and motivate continued evolution of CRN institutions as the nation's premier learning health care systems. Supported by U24 CA171524.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer Research Committee"

1

Sewak, Mihir S. "Application of Committee Neural Networks for Gene Expression Based Leukemia Classification." University of Akron / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=akron1205514796.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cancer Research Committee"

1

Environment, United States Congress House Committee on Energy and Commerce Subcommittee on Health and the. Cancer survival rates: Hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, first session, June 29, 1987. Washington: U.S. G.P.O., 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Health, United States Congress House Committee on Energy and Commerce Subcommittee on. NCI cancer research: Today's progress, tomorrow's challenges : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, March 23, 2010. Washington: U.S. Government Printing Office, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

United States. Congress. House. Committee on Commerce. Subcommittee on Health and the Environment. The state of cancer research: Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives, One Hundred Fifth Congress, second session, July 20, 1998. Washington: U.S. G.P.O., 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies. Cancer research and prevention: Hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Seventh Congress, second session, special hearing, June 4, 2002, Washington, DC. Washington: U.S. G.P.O., 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies. Winning the race against cancer: Hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Ninth Congress, second session, special hearing, July 28, 2006, Iowa City, Iowa. Washington: U.S. G.P.O., 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

National Health Service. Central Research and Development Committee. R & D priorities in cancer: Report to the NHS Central Research and Development Committee. London: NHS, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Formaldehyde study: Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, second session, July 28, 1986. Washington: U.S. G.P.O., 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Formaldehyde study: Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, second session, July 28, 1986. Washington: U.S. G.P.O., 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Formaldehyde study: Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, second session, July 28, 1986. Washington: U.S. G.P.O., 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Prostate cancer: Hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Sixth Congress, first session, special hearing. Washington: U.S. G.P.O., 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer Research Committee"

1

Keating, Peter, and Alberto Cambrosio. "Cancer Research and Protocol Patients: From Clinical Material to Committee Advisors." In Cancer Patients, Cancer Pathways, 161–85. London: Palgrave Macmillan UK, 2012. http://dx.doi.org/10.1057/9781137272089_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Al-Hussaini, Maysa. "Case Study: Research Ethics Committee at King Hussein Cancer Center, Jordan." In Research Ethics Forum, 311–24. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-65266-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Translating Cancer Research into Cancer Care: Final Report of the Long Range Planning Committee." In Health Informatics, 5–16. New York, NY: Springer New York, 2002. http://dx.doi.org/10.1007/978-1-4613-0063-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bezerra, Luciete Alves, João Roberto Ferreira de Melo, Paulo Roberto Maciel Lyra, and Rita de Cássia Fernandes de Lima. "Applications of the Use of Infrared Breast Images." In Biomedical Computing for Breast Cancer Detection and Diagnosis, 250–89. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-3456-4.ch012.

Full text
Abstract:
In this chapter, procedures for and applications of using infrared (IR) imaging that have been developed will be presented and proposed means by which a better detailed understanding of breast cancer can be reached. It will be shown how such applications can be used as a basis for enhancing the use of breast thermographic imaging as a user-friendly and inexpensive tool for the early detection of breast cancer. The authors intend to show that IR imaging can also be used to validate temperature profiles that have been calculated and to classify breast abnormalities as set out in previous chapters. IR images can also be used to estimate thermophysical properties of the breast, and discussion of how this is done is included. The IR images were acquired at the Outpatients Clinic of Mastology of the Hospital das Clínicas of the Federal University of Pernambuco (HC/UFPE). The research project was registered in the Brazilian Health Ministry (CEP/CCS/UFPE nº 279/05) after being approved by the Ethics Committee of UFPE.
APA, Harvard, Vancouver, ISO, and other styles
5

Davis, Susan G. "Sex Researcher." In Dirty Jokes and Bawdy Songs, 37–64. University of Illinois Press, 2019. http://dx.doi.org/10.5622/illinois/9780252042614.003.0003.

Full text
Abstract:
In the years 1934-40, Gershon Legman defined his life’s work and taught himself the skills he would use in his richly productive research career. Moving to New York City after graduating high school, at the height of the Great Depression, he tried to make a career for himself as a writer about sex. Legman was taken on as a sex researcher and bibliographer for the eminent gynecologist Robert L. Dickinson. He also worked as a book scout and courier in underground erotica publishing, shuttling merchandise around for the book dealer Frances Stellof. He learned printing, layout, binding, and book design in the workshop of Jacob Brussel. His first publication as a folklorist, a glossary of homosexual slang, was researched with Thomas Painter for the Committee on Sex Variants, under Dr. Dickinson’s auspices. Also, during these years, Legman aimed to shatter the censorship barriers in literary publishing. He worked as a dollar-a-page pornographer, impersonating Henry Miller, among others. With Brussel, he brought out the first American edition of Henry Miller’s Tropic of Cancer and under a pseudonym published his own first book, Oragenitalism, a treatise on oral sex. Both volumes were highly illegal, and when they were seized in a police raid, Legman barely escaped arrest.
APA, Harvard, Vancouver, ISO, and other styles
6

"potential risk of cancer to humans; and chemicals which CAG reviewed because one or more of three organizations (The International Agency for Research on Cancer, the National Toxicology Program Bioassay Program, and the Food and Drug Administration of the U.S. Department of Health and Human Services) concluded that these chemicals are potential human carcinogens. Report of the TSCA Interagency Testing Committee to the Administrator, Environmental Protection Agency Section 4(e) of the Toxic Substances Control Act (TSCA) (P.L. 94469) established the TSCA Interagency Testing Committee (lTC) with representation from many of the Federal research and regulatory agencies. This Committee has the continuing responsibility to identify and recommend to the Administrator of the Environmental Protection Agency, chemical substances or mixtures which should be tested to determine their hazard to human health or the environment. In the ITC review and recommendation of selected chemicals, priority attention given to those individual or groups of chemical substances or mixtures which are known to cause or contribute to, or which are suspected of causing or contributing to cancer, gene mutations, or birth defects. The list, and reasons for making each recommendation, are required to be published in the Federal Register. Since 1977, the lTC has published eight reports which contain a total of 46 chemical substances or categories of chemicals. One chemical has been removed from the 4( e) Priority List because EPA responded to the Committee's recommendation for testing. Toxic Substances Control Act: Substantial Risk Notification Under Section 8(e) of the Toxic Substances Control Act of 1976 (TSCA), anyone who obtains information which reasonably supports the conclusion that a substance presents a substantial risk of injury to human health or the environment must notify the Environmental Protection Agency within days. These notices are then reviewed by the Office of Pesticides and Toxic Substances. An initial evaluation of the substance is prepared containing, if appropriate, followup questions to the submitter, referrals." In Dangerous Properties of Industrial and Consumer Chemicals, 20. CRC Press, 1994. http://dx.doi.org/10.1201/9781482293500-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"screen. Chemicals which are shown to be mutagenic in Phase I assays progress to Phase II. In addition, a certain number of chemicals giving negative results in Phase I are committed also to further testing in Phase II, based primarily on known biological activity of structurally related compounds, and on estimated levels of human exposure. Chemicals which are positive mutagens in Phase progress to Phase III. III. WORLD HEALTH ORGANIZATION'S (WHO) INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans In the World Health Organization's International Agency for Research on Cancer (IARC) initiated a program of evaluation of the carcinogenic risk of chemicals to humans. "The objective of the program to elaborate and publish in the form of monographs, critical reviews of data on carcinogenicity for groups of chemicals to which humans are known to be exposed, to evaluate these data in terms of human risk . . . and to indicate where additional research efforts are needed." The IARC Monographs are recognized an authoritative source of information on the carcinogenicity of environmental chemicals. The first users' survey, made in 1976, indicates that the monographs are consulted routinely by various agencies in 24 countries. IV. OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (OSHA) A List of Substances Which May Be Candidates for Further Scientific Review and Possible Identification, Classification and Regulation Potential Occupational Carcinogens. Publication of this list by the Occupational Safety and Health Administration the first action taken in following the "Cancer Standard" procedures promulgated by OSHA in January, 1980." In Dangerous Properties of Industrial and Consumer Chemicals, 17. CRC Press, 1994. http://dx.doi.org/10.1201/9781482293500-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer Research Committee"

1

"Organizing Committee." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Permata, Tiara Bunga Mayang, Steven Octavianus, and Soehartati Gondhowiardjo. "Abstract 89: National Cancer Control Committee (NCCC) as Cancer-Related Non-Governmental Organizations (NGOs) Alliance: Strengthening Partnerships among the NGOs as Part of the Cancer Control Program." In Abstracts: 9th Annual Symposium on Global Cancer Research; Global Cancer Research and Control: Looking Back and Charting a Path Forward; March 10-11, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7755.asgcr21-89.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lemos, Nayara Alves de Freitas, Ruffo de Freitas-Junior, Rebeca Mota Gouveia, and Elisângela Silveira Lacerda. "R337H MUTATION AND DUCTAL CARCINOMA IN SITU OF THE BREAST." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2003.

Full text
Abstract:
Objective: To identify the prevalence of the founding variant c.1010G>A (R337H) in the TP53 gene in patients with ductal carcinoma in situ (DCIS). Methods: This is a cross-sectional study, carried out using data from the Goiania PopulationBased Cancer Registry, in partnership with the team from the Molecular and Cytogenetic Genetics Laboratory of the Federal University of Goias and Clinical Research Unit/HC. Peripheral venous blood collections, DNA extraction, and Sanger genetic sequencing were carried out in 27 samples from unselected patients diagnosed with DCIS in the period between 1994 and 2010, who agreed to participate in the research by signing the free and informed consent form. This work was approved by the Research Ethics Committee of Hospital das Clínicas/UFG, as a proposing institution, and Research Ethics Committee of the Co-participant Institution Hospital Araújo Jorge/Association for Combating Cancer in Goiás (ACCG) in attention to the resolution CNS: 466/2012 and its complementaries (1,940,921). Results: In our study, conducted in midwestern Brazil with a population of women with DCIS not selected for family history and involving 27 samples, 2 cases (7.4%) of the pathogenic TP53 R337H mutation were found. Conclusions: The present study showed that the prevalence of the founding variant c.1010G>A (R337H) in the TP53 gene in patients with DCIS proved to be considerably high, comparing the same rate found in other Brazilian studies for invasive breast carcinoma. This study warrants that there is a need for further studies testing not only the TP53 gene, but also other genes related to hereditary breast and ovarian cancer syndrome in DCIS. Although DCIS is a non-obligate precursor to invasive carcinoma, we highlighted the facts that strengthen the reflection on better genetic research in women with DCIS.
APA, Harvard, Vancouver, ISO, and other styles
4

Costa, Rafael Everton Assunção Ribeiro da, Fergus Tomás Rocha de Oliveira, Eduarda Norberto Siqueira, Ana Lúcia Nascimento Araújo, and Sabas Carlos Vieira. "RECURRENCE IN MALE BREAST CANCER: A CASE SERIES." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2079.

Full text
Abstract:
Introduction: Male breast cancer (MBC) is a very rare disease, which accounts for approximately 1.0% of all breast cancers and around 0.17%–1.0% of all male malignancies, more common in the age group of 60 years, and 93.7% of cases of MBC are histologically classified as the invasive carcinoma of no special type (ICNS). Treatment (i.e., surgery, radiotherapy, chemotherapy, and hormone therapy) and prognosis are similar to breast cancer in women. The aim of this study was to describe five MBC cases and to analyze the occurrence of relapse in a follow-up of 88 months (36–180 months). Case series: The mean age of five patients of the case series was 69 years (57–88 years). All cases were histologically classified as ICNS. The mean tumor size of the series was 2.6 cm (1.0–5.2 cm). One patient of the case series presented with perineural invasion, and another case had axillary node involvement (+5/15). None of the patients had metastasis at the time of diagnosis. All patients underwent surgery. Regarding complementary treatment, one patient underwent chemotherapy, radiotherapy, and hormone therapy (i.e., a case with axillary node involvement); two others underwent chemotherapy and hormone therapy; and the remaining two cases underwent treatment only with hormone therapy. One patient had systemic recurrence with the presentation of bone metastasis (75 months of follow-up). The study was approved by a Research Ethics Committee, under CAAE No 30154720.0.0000.5209. Conclusion: With a mean follow-up of 88 months (36–180 months), one of the five patients in the series (20%) showed systemic recurrence with bone metastasis.
APA, Harvard, Vancouver, ISO, and other styles
5

Costa, Rafael Everton Assunção Ribeiro da, Fergus Tomás Rocha de Oliveira, Eduarda Norberto Siqueira, Ana Lúcia Nascimento Araújo, and Sabas Carlos Vieira. "CUTANEOUS AND BONE METASTASIS OF OCCULT BREAST CANCER: CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2078.

Full text
Abstract:
Introduction: Occult breast cancer (OBC) is defined as a metastatic carcinoma that occurs mainly in the axillary lymph nodes, derived from a primary malignant breast tumor undetectable by clinical and radiological analyses. OBC is a rare disease accounting for 0.3%–1.0% of all breast cancers, which occurs more commonly at the age of around 55 years. The OBC represents a rare event (especially with the manifestation of systemic metastases) and a major diagnostic challenge. Thus, the aim of this study was to report a case of OBC with the primary manifestation of cutaneous metastases and the subsequent detection of bone metastasis. Case report: A 70-year-old female patient, G1P0A0, nonsmoker, nonalcoholic, with hypertension, and sedentary lifestyle, exhibited multiple metastatic cutaneous lesions in the left cervical region (2 cm), of the left breast (3 cm), left axilla (0.5 cm), left subscapular region (3 cm), and in the second and fifth left chirodactyls (using anastrozole for 1 month). Mammography, ultrasonography, and magnetic resonance imaging of the breast were performed, and no structural alterations were detected in any of these tests. Biopsy of the skin lesion of the left cervical region and immunohistochemistry also indicated positive estrogen receptors (ER), progesterone receptors (PR), and GATA-binding protein 3 (GATA-3; compatible with breast cancer metastasis), establishing the diagnosis of occult breast cancer with cutaneous metastasis. The use of anastrozole was maintained. The scintigraphy was performed, indicating bone metastasis in the right coastal arcs 8 and 9 considered stable in a new test performed 8 months later. All cutaneous metastatic lesions disappeared 2 years later, with the exception of a lesion in the left cervical region, where surgical resection was indicated. The study was approved by a Research Ethics Committee, under CAAE No 30154720.0.0000.5209. Conclusion: The patient exhibited an excellent response to anastrozole and is in excellent general condition with the stability of bone metastasis.
APA, Harvard, Vancouver, ISO, and other styles
6

Almeida, Raissa Janine de, Carolina Terra de Moraes Luizaga, José Eluf-Neto, Eduardo Carvalho Pessoa, Amanda de Moraes Mamede Chiarotti, Rainer de Almeida Souza, and Cristiane Murta Nascimento. "THE IMPACT OF EDUCATION ON BREAST CANCER SURVIVAL IN THE STATE OF SÃO PAULO." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2108.

Full text
Abstract:
Objectives: To estimate 5- and 10-year breast cancer–specific survival probabilities of patients admitted in the hospitalbased cancer registry (HBCR) of the Fundação Oncocentro de São Paulo (FOSP, in Portuguese) and to assess the prognostic factors for this neoplasm. Methods: Historical cohort study that included women with breast cancer included in HBCRFOSP and diagnosed between 2002 and 2012. The event of interest was breast cancer–specific mortality. Living cases at the end of follow-up (December 31, 2017), loss to follow-up, and death other than that due to breast cancer were considered censored on the date of the last contact or date of death. Descriptive analysis and survival analysis were performed using the Kaplan–Meyer method. Survival curves were compared using the log-rank test. HR and 95%CI were estimated using Cox proportional hazards model. This study was approved by the Human Research Ethics Committee of the Botucatu Medical School, São Paulo State University, Brazil. Results: The HBCR-FOSP registered 53,146 cases of invasive breast cancer between 2002 and 2012. The median age at diagnosis was 55.9 years. The 5- and 10-year breast cancer–specific survival for the entire cohort was 76.1% (95%CI 75.7–76.5) and 64.8% (95%CI 64.2–65.3), respectively. In the multivariate analysis, the factors clinical stage and educational level were with the greatest impact on survival. The other factors associated with prognosis were age at diagnosis, histological type, and year of diagnosis. Conclusion: The results show that patients in more advanced stages and with less level of education have a higher risk of death from breast cancer. Besides, these findings may contribute to the development of policies for the identification of breast tumors at earlier stages.
APA, Harvard, Vancouver, ISO, and other styles
7

Almeida, Raissa Janine de, Carolina Terra de Moraes Luizaga, and Cristiane Murta Nascimento. "SURVIVAL AND PROGNOSTIC FACTORS OF BREAST CANCER IN WOMEN IN THE STATE OF SÃO PAULO." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1031.

Full text
Abstract:
Introduction: Breast cancer is the first most common malignancy in the female population worldwide. Monitoring the survival of women with breast cancer has been a strategy frequently adopted at the international level as a measure to assess the progress of public policies for the control of the disease. Objectives: To estimate the probabilities of five and ten year survival and to investigate the prognostic factors of women with breast cancer included in the hospital-based cancer registry (RHC) of Fundação Oncocentro de São Paulo (FOSP). Methods: It was a historical cohort study. The sample consisted of women with breast cancer diagnosed between 2002 and 2012 and included in the RHC-FOSP. The event of interest was breast cancer-specific mortality. Living cases at the end of follow-up (December 31, 2017), loss to follow-up, and death other than that due to breast cancer were considered censored on the date of the last contact or date of death. Descriptive analysis and survival analysis were performed using the Kaplan-Meyer method. Survival curves were compared using the log-rank test. Hazard ratios (HR) and their 95%CI were estimated using Cox’s proportional hazards model. This study was approved by the Human Research Ethics Committee of the Botucatu Medical School, São Paulo State University, Brazil. Results: Between 2002 and 2012, 53,146 cases of invasive breast cancer were registered at RHC-FOSP. The median age of women at diagnosis was 55.9 years. By the end of the follow-up, 20,683 patients died and 71.4% of such deaths were due to breast cancer. The five and ten year breast cancer-specific survival for the entire cohort was 76.1% (95%CI 75.7–76.5) and 64.8% (95%CI 64.2–65.3), respectively. In the multivariate analysis, the factors associated with prognosis were: age at diagnosis, year of diagnosis, educational level, grouped clinical stage, and histological type. Conclusions: Specific survival for breast cancer in the state of São Paulo is significantly associated with several characteristics. The knowledge of these characteristics can contribute to the development of public policies in the area.
APA, Harvard, Vancouver, ISO, and other styles
8

Almeida, Raissa Janine de, Arthur Felipe Decker, Carolina Terra de Moraes Luizaga, and Cristiane Murta Nascimento. "BREAST CANCER IN WOMEN: CHARACTERIZATION OF CASES INCLUDED IN THE HOSPITAL-BASED CANCER REGISTRY OF THE STATE OF SÃO PAULO AND FACTORS ASSOCIATED WITH ADVANCED STAGES." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1030.

Full text
Abstract:
Introduction: Breast cancer is a public health problem worldwide, being the most common malignancy in the female population. It is a potentially curable disease with an early diagnosis. The advanced stage at the time of diagnosis is associated with increased morbidity and low survival for the patients. Objectives: To describe the sociodemographic, clinical, and anatomopathological characteristics of breast cancer cases in women included in the hospital-based cancer registry (RHC) of Fundação Oncocentro de São Paulo (FOSP), and to investigate factors associated with the clinical stage at diagnosis. Methods: The study design was a case series. The sample consisted of women with breast cancer diagnosed between 2000 and 2014 and included in the RHC-FOSP. The outcome variable was a clinical-stage (stage 0–II versus III–IV). The explanatory variables were age at diagnosis and educational level. This study was approved by the Human Research Ethics Committee of the Botucatu Medical School, São Paulo State University, Brazil. Results: The study included 84,987 women with in situ and invasive breast cancer diagnosed between 2000 and 2014. The average age of women at diagnosis was 56.7 years (95%CI 56.6–56.8 years). Sixty-five percent of cases completed elementary school or less and the most frequent histological type was ductal carcinoma (77.2%). During the study period, there was a slight decrease in the proportion of tumors in more advanced stages, from 39.8% in 2000 to 32.6% in 2014. There was a statistically significant association between age at diagnosis and educational level with the women’s grouped clinical stage. Women of older age and those with a higher education level had reduced odds ratios of having tumors in more advanced stages at the time of diagnosis. Conclusions: These findings may contribute to the development of policies for the identification of breast tumors at earlier stages.
APA, Harvard, Vancouver, ISO, and other styles
9

Kohara, Izumi, Noriko Fujiwara, Hiroko Nakahama, Kojiro Shimozuma, Hiroyuki Fujiwara, Keiichi Fujiwara, and Mitsuaki Suzuki. "EP190/#579 Evaluation of a journal club hosted by the research nurse committee in a Japanese gynecologic cancer clinical trials group." In IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ramos, Dandara Rocha, Maria Fernanda Passos Rocha Ramos, Paulus Fabricio Mascarenhas Ramos, and Katia de Miranda Avena. "DIAGNOSIS OF BREAST CANCER IN BRAZIL: REFLECTION ON THE IMPACT OF THE COVID-19 PANDEMIC." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2005.

Full text
Abstract:
Objective: To compare the number of breast cancer diagnoses performed in the public health system in Brazil, in the period from 2015 to 2020, analyzing the effects of the coronavirus disease 2019 (COVID-19) pandemic. Methodology: This is an observational, cross-sectional study, with a descriptive and quantitative approach, which is carried out with secondary data provided by the Cancer Information System (SISCAN/DATASUS), considering two time frames — before the pandemic (2015–2019) and during the pandemic (2020). The study included women diagnosed with breast cancer, who underwent mammography between 2015 and 2020. Appreciation by the Research Ethics Committee was waived because public, aggregated data were used, without identifying the participants. Results: Between 2015 and 2020, 14,598,318 mammograms were performed in Brazil. The temporal analysis shows a gradual upward behavior in all years, reaching a growth of 49.6% from 2015 (n=2,047,295) to 2019 (n=3,063,022). In the year 2020, there is a significant drop (39.8%) in the number of mammograms performed (n=1,843,182). From 2015 to 2020, 197,368 breast cancer diagnoses were carried out in Brazil. As with the monographs, in the year of the pandemic, a significant drop (46.9%) was demonstrated in the diagnoses performed (n=22,167), a figure that represents only 33.4% of the estimate for 2020 made by the National Cancer Institute (n=66,280). Conclusions: With the emergence of the COVID-19 pandemic and the magnitude taken by it, there was a significant impact on the screening, monitoring, and treatment of breast cancer in the country. It is possible that measures of social isolation to contain the virus contributed to this behavior, causing underdiagnosis and future expectations of less favorable prognosis. It is believed that this scenario will worsen in 2021 in view of the number of cases that are no longer diagnosed, a fact that possibly will reflect on the severity of the cases and the costs for public health.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer Research Committee"

1

Smit, Amelia, Kate Dunlop, Nehal Singh, Diona Damian, Kylie Vuong, and Anne Cust. Primary prevention of skin cancer in primary care settings. The Sax Institute, August 2022. http://dx.doi.org/10.57022/qpsm1481.

Full text
Abstract:
Overview Skin cancer prevention is a component of the new Cancer Plan 2022–27, which guides the work of the Cancer Institute NSW. To lessen the impact of skin cancer on the community, the Cancer Institute NSW works closely with the NSW Skin Cancer Prevention Advisory Committee, comprising governmental and non-governmental organisation representatives, to develop and implement the NSW Skin Cancer Prevention Strategy. Primary Health Networks and primary care providers are seen as important stakeholders in this work. To guide improvements in skin cancer prevention and inform the development of the next NSW Skin Cancer Prevention Strategy, an up-to-date review of the evidence on the effectiveness and feasibility of skin cancer prevention activities in primary care is required. A research team led by the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW, was contracted to undertake an Evidence Check review to address the questions below. Evidence Check questions This Evidence Check aimed to address the following questions: Question 1: What skin cancer primary prevention activities can be effectively administered in primary care settings? As part of this, identify the key components of such messages, strategies, programs or initiatives that have been effectively implemented and their feasibility in the NSW/Australian context. Question 2: What are the main barriers and enablers for primary care providers in delivering skin cancer primary prevention activities within their setting? Summary of methods The research team conducted a detailed analysis of the published and grey literature, based on a comprehensive search. We developed the search strategy in consultation with a medical librarian at the University of Sydney and the Cancer Institute NSW team, and implemented it across the databases Embase, MEDLINE, PsycInfo, Scopus, Cochrane Central and CINAHL. Results were exported and uploaded to Covidence for screening and further selection. The search strategy was designed according to the SPIDER tool for Qualitative and Mixed-Methods Evidence Synthesis, which is a systematic strategy for searching qualitative and mixed-methods research studies. The SPIDER tool facilitates rigour in research by defining key elements of non-quantitative research questions. We included peer-reviewed and grey literature that included skin cancer primary prevention strategies/ interventions/ techniques/ programs within primary care settings, e.g. involving general practitioners and primary care nurses. The literature was limited to publications since 2014, and for studies or programs conducted in Australia, the UK, New Zealand, Canada, Ireland, Western Europe and Scandinavia. We also included relevant systematic reviews and evidence syntheses based on a range of international evidence where also relevant to the Australian context. To address Question 1, about the effectiveness of skin cancer prevention activities in primary care settings, we summarised findings from the Evidence Check according to different skin cancer prevention activities. To address Question 2, about the barriers and enablers of skin cancer prevention activities in primary care settings, we summarised findings according to the Consolidated Framework for Implementation Research (CFIR). The CFIR is a framework for identifying important implementation considerations for novel interventions in healthcare settings and provides a practical guide for systematically assessing potential barriers and facilitators in preparation for implementing a new activity or program. We assessed study quality using the National Health and Medical Research Council (NHMRC) levels of evidence. Key findings We identified 25 peer-reviewed journal articles that met the eligibility criteria and we included these in the Evidence Check. Eight of the studies were conducted in Australia, six in the UK, and the others elsewhere (mainly other European countries). In addition, the grey literature search identified four relevant guidelines, 12 education/training resources, two Cancer Care pathways, two position statements, three reports and five other resources that we included in the Evidence Check. Question 1 (related to effectiveness) We categorised the studies into different types of skin cancer prevention activities: behavioural counselling (n=3); risk assessment and delivering risk-tailored information (n=10); new technologies for early detection and accompanying prevention advice (n=4); and education and training programs for general practitioners (GPs) and primary care nurses regarding skin cancer prevention (n=3). There was good evidence that behavioural counselling interventions can result in a small improvement in sun protection behaviours among adults with fair skin types (defined as ivory or pale skin, light hair and eye colour, freckles, or those who sunburn easily), which would include the majority of Australians. It was found that clinicians play an important role in counselling patients about sun-protective behaviours, and recommended tailoring messages to the age and demographics of target groups (e.g. high-risk groups) to have maximal influence on behaviours. Several web-based melanoma risk prediction tools are now available in Australia, mainly designed for health professionals to identify patients’ risk of a new or subsequent primary melanoma and guide discussions with patients about primary prevention and early detection. Intervention studies have demonstrated that use of these melanoma risk prediction tools is feasible and acceptable to participants in primary care settings, and there is some evidence, including from Australian studies, that using these risk prediction tools to tailor primary prevention and early detection messages can improve sun-related behaviours. Some studies examined novel technologies, such as apps, to support early detection through skin examinations, including a very limited focus on the provision of preventive advice. These novel technologies are still largely in the research domain rather than recommended for routine use but provide a potential future opportunity to incorporate more primary prevention tailored advice. There are a number of online short courses available for primary healthcare professionals specifically focusing on skin cancer prevention. Most education and training programs for GPs and primary care nurses in the field of skin cancer focus on treatment and early detection, though some programs have specifically incorporated primary prevention education and training. A notable example is the Dermoscopy for Victorian General Practice Program, in which 93% of participating GPs reported that they had increased preventive information provided to high-risk patients and during skin examinations. Question 2 (related to barriers and enablers) Key enablers of performing skin cancer prevention activities in primary care settings included: • Easy access and availability of guidelines and point-of-care tools and resources • A fit with existing workflows and systems, so there is minimal disruption to flow of care • Easy-to-understand patient information • Using the waiting room for collection of risk assessment information on an electronic device such as an iPad/tablet where possible • Pairing with early detection activities • Sharing of successful programs across jurisdictions. Key barriers to performing skin cancer prevention activities in primary care settings included: • Unclear requirements and lack of confidence (self-efficacy) about prevention counselling • Limited availability of GP services especially in regional and remote areas • Competing demands, low priority, lack of time • Lack of incentives.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer Research Committee' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography